The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...
MedPage Today on MSN
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...
These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...
Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, ...
Lilly to present new clinical data for Verzenio and multiple novel pipeline programMEs at the 2025 ESMO annual meeting: Indianapolis Tuesday, October 14, 2025, 09:00 Hrs [IST] Eli ...
At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...
Researchers appear to have found a solution for breast cancer patients who do not respond well enough to the common treatment ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback